Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
复制标题
通过新型二价配体诱导 mu 阿片类药物 (MOP) 和 2 型胆囊收缩素 (CCK2) 受体的结合。
DOI:
10.1021/jm800174p
复制
发表时间:
2009
影响因子:
7.3
通讯作者:
Portoghese,PhilipS
中科院分区:
文献类型:
--
作者:
Zheng,Yaguo;Akgün,Eyup;Harikumar,KaleeckalG;Hopson,Jessika;Powers,MichaelD;Lunzer,MaryM;Miller,LaurenceJ;Portoghese,PhilipS
Both μ-opioid (MOP) and type 2 cholecystokinin (CCK2) receptors are present in areas of the central nervous system that are involved in modulation of pain processing. We conducted bioluminescence resonance energy transfer (BRET) studies on COS cells coexpressing MOP and CCK2receptors to determine whether receptor heterodimerization is involved in such modulation. These studies revealed the absence of constitutive or monovalent ligand-induced heterodimerization. Heterodimerization of MOP and CCK2receptors therefore is unlikely to be responsible for the opposing effects between morphine and CCK in the CNS. However, association was induced, as indicated by a positive BRET signal, on exposure of the cells to bivalent ligands containing μ-opioid agonist and CCK2receptor antagonist pharmacophores linked through spacers containing 16−22 atoms but not with a shorter (9-atom) spacer. These studies demonstrate for the first time that an appropriately designed bivalent ligand is capable of inducing association of G-protein-coupled receptors. The finding that opioid tolerance studies with these ligands in mice showed no correlation with the BRET data is consistent with the absence of association of MOP and CCK2receptors in vivo.